Smartphone App for Improving Self-Awareness of Adherence to Edoxaban Treatment in Patients With Atrial Fibrillation (ADHERE-App Trial): Randomized Controlled Trial

J Med Internet Res. 2024 Nov 21:26:e65010. doi: 10.2196/65010.

Abstract

Background: Adherence to oral anticoagulant therapy is essential to prevent ischemic stroke in patients with atrial fibrillation (AF).

Objective: This study aimed to evaluate whether smartphone app-based interventions improve medication adherence in patients with AF.

Methods: This open-label, multicenter randomized controlled trial (ADHERE-App [Self-Awareness of Drug Adherence to Edoxaban Using an Automatic App Feedback System] study) enrolled patients with AF treated with edoxaban for stroke prevention. They were randomly assigned to app-conditioned feedback (intervention; n=248) and conventional treatment (control; n=250) groups. The intervention group received daily alerts via a smartphone app to take edoxaban and measure blood pressure and heart rate at specific times. The control group received only standard, guideline-recommended care. The primary end point was edoxaban adherence, measured by pill count at 3 or 6 months. Medication adherence and the proportion of adequate medication adherence, which was defined as ≥95% of continuous medication adherence, were evaluated.

Results: Medication adherence at 3 or 6 months was not significantly different between the intervention and control groups (median 98%, IQR 95%-100% vs median 98%, IQR 91%-100% at 3 months, P=.06; median 98%, IQR 94.5%-100% vs median 97.5%, IQR 92.8%-100% at 6 months, P=.15). However, the proportion of adequate medication adherence (≥95%) was significantly higher in the intervention group at both time points (76.8% vs 64.7% at 3 months, P=.01; 73.9% vs 61% at 6 months, P=.007). Among patients aged >65 years, the intervention group showed a higher medication adherence value and a higher proportion of adequate medication adherence (≥95%) at 6 months.

Conclusions: There was no difference in edoxaban adherence between the groups. However, the proportion of adequate medication adherence was higher in the intervention group, and the benefit of the smartphone app-based intervention on medication adherence was more pronounced among older patients than among younger patients. Given the low adherence to oral anticoagulants, especially among older adults, using a smartphone app may potentially improve medication adherence.

Trial registration: International Clinical Trials Registry Platform KCT0004754; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=28496&search_page=L.

International registered report identifier (irrid): RR2-10.1136/bmjopen-2021-048777.

Keywords: anticoagulants; atrial fibrillation; digital health; medication adherence; mobile apps; mobile phone.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / therapeutic use
  • Female
  • Humans
  • Male
  • Medication Adherence* / statistics & numerical data
  • Middle Aged
  • Mobile Applications
  • Pyridines* / therapeutic use
  • Smartphone*
  • Thiazoles* / administration & dosage
  • Thiazoles* / therapeutic use

Substances

  • edoxaban
  • Thiazoles
  • Pyridines
  • Anticoagulants
  • Factor Xa Inhibitors